Join
Live feed
·
PRReleasevia Quantisnow
AbbVie Inc. logo

AbbVie Submits Application for Risankizumab (SKYRIZI®) in Moderate to Severe Crohn's Disease to European Medicines Agency (EMA)

ByQuantisnow·Wall Street's wire, on your screen.
ABBV· AbbVie Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ABBV (AbbVie Inc.) and more on Quantisnow.